These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9864183)

  • 41. Iron chelators and iron toxicity.
    Brittenham GM
    Alcohol; 2003 Jun; 30(2):151-8. PubMed ID: 12957300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ; Neocleous K; Kolnagou A
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
    Obejero-Paz CA; Yang T; Dong WQ; Levy MN; Brittenham GM; Kuryshev YA; Brown AM
    J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. UV and fluorescence spectral changes induced by neodymium binding of N,N'-ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N' diacetic acid.
    Wang Z; Yang B
    Spectrochim Acta A Mol Biomol Spectrosc; 2006 Nov; 65(3-4):946-9. PubMed ID: 16684618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.
    Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN
    J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A non-human primate model for the study of oral iron chelators.
    Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
    Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
    Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
    Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
    Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
    J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
    Hallaway PE; Eaton JW; Panter SS; Hedlund BE
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile.
    Nasrallah GK; Salem R; Da'as S; Al-Jamal OLA; Scott M; Mustafa I
    Neurotoxicol Teratol; 2019; 72():29-38. PubMed ID: 30710618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
    Cappellini MD; Bejaoui M; Agaoglu L; Porter J; Coates T; Jeng M; Lai ME; Mangiagli A; Strauss G; Girot R; Watman N; Ferster A; Loggetto S; Abish S; Cario H; Zoumbos N; Vichinsky E; Opitz H; Ressayre-Djaffer C; Abetz L; Rofail D; Baladi JF
    Clin Ther; 2007 May; 29(5):909-917. PubMed ID: 17697909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.
    Liu Z; Qiao J; Nagy T; Xiong MP
    J Control Release; 2018 Aug; 283():84-93. PubMed ID: 29792889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral iron chelators.
    Cappellini MD; Pattoneri P
    Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.